Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

[1]  S. Pocock,et al.  Clinical Trials: A Practical Approach , 1984 .

[2]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[3]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[4]  S. Steingard,et al.  Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. , 1991, Archives of general psychiatry.

[5]  M. Espeland,et al.  Analysis strategies for serial multivariate ultrasonographic data that are incomplete. , 1992, Statistics in medicine.

[6]  Jean Addington,et al.  Reliability and validity of a depression rating scale for schizophrenics , 1991, Schizophrenia Research.

[7]  P. Bech,et al.  The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity , 1993, Acta psychiatrica Scandinavica.

[8]  H Goldstein,et al.  Multilevel time series models with applications to repeated measures data. , 1994, Statistics in medicine.

[9]  M. Coffey,et al.  A Brief Mental Health Outcome Scale , 1995, British Journal of Psychiatry.

[10]  C. Stone,et al.  Further evidence of a dose-response threshold for haloperidol in psychosis. , 1995, The American journal of psychiatry.

[11]  S. Kapur,et al.  High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. , 1996, The American journal of psychiatry.

[12]  P. Hayward,et al.  Compliance therapy in psychotic patients: randomised controlled trial , 1996, BMJ.

[13]  S. Kapur,et al.  The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study , 1997, Psychopharmacology.

[14]  T. Hergueta,et al.  The mini international neuropsychiatric interview , 1998, European Psychiatry.

[15]  S. Kapur,et al.  Pharmacotherapy of first-episode schizophrenia , 1998, British Journal of Psychiatry.

[16]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[17]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[18]  J. Lieberman,et al.  Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. , 1999, Archives of general psychiatry.

[19]  Rury R. Holman,et al.  Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) , 1999 .

[20]  S. Leucht,et al.  Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials , 1999, Schizophrenia Research.

[21]  S. Evans,et al.  Application and Results of the Manchester Short Assessment of Quality of Life (Mansa) , 1999, The International journal of social psychiatry.

[22]  S. Kapur,et al.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.

[23]  N Freemantle,et al.  Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis , 2000, BMJ : British Medical Journal.

[24]  Michael B. First,et al.  Handbook of Psychiatric Measures , 2000 .

[25]  H. Meltzer,et al.  A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study , 2002, International clinical psychopharmacology.

[26]  S. Tanada,et al.  Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. , 2002, Archives of general psychiatry.

[27]  S. Leucht,et al.  New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis , 2003, The Lancet.

[28]  I. Glick,et al.  A meta-analysis of the efficacy of second-generation antipsychotics , 2003, Schizophrenia Research.

[29]  R. Kahn,et al.  Sex differences in the risk of schizophrenia: evidence from meta-analysis. , 2003, Archives of general psychiatry.

[30]  Claude Colette,et al.  Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). , 2003, Diabetes care.

[31]  June Corwin,et al.  Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. , 2003, JAMA.

[32]  S. Leucht,et al.  New generation antipsychotics for first episode schizophrenia. , 2003, The Cochrane database of systematic reviews.

[33]  J. Lieberman,et al.  Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. , 2003, The American journal of psychiatry.

[34]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[35]  W. Heiden,et al.  When and how does schizophrenia produce social deficits? , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[36]  M. Hummer,et al.  Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. , 2005, Archives of general psychiatry.

[37]  R. Kahn,et al.  The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial , 2005, Schizophrenia Research.

[38]  J. Lieberman,et al.  Antipsychotic drug effects on brain morphology in first-episode psychosis. , 2005, Archives of general psychiatry.

[39]  Philip D. Harvey,et al.  Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. , 2005, The American journal of psychiatry.

[40]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[41]  J. Lieberman,et al.  Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations , 2006, Nature Reviews Drug Discovery.

[42]  U. Gschwandtner,et al.  Early detection and treatment of schizophrenia: how early? , 2006, Acta psychiatrica Scandinavica. Supplementum.

[43]  Jean-Paul Cristol,et al.  Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. , 2006, JAMA.

[44]  J. Lieberman,et al.  Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. , 2006, The American journal of psychiatry.

[45]  J. Kane,et al.  Linking the PANSS, BPRS, and CGI: Clinical Implications , 2006, Neuropsychopharmacology.

[46]  J. Lieberman,et al.  Olanzapine and haloperidol in first episode psychosis: Two-year data , 2006, Schizophrenia Research.

[47]  J. Lieberman,et al.  Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. , 2007, The American journal of psychiatry.

[48]  E. Ferrannini,et al.  Beta-cell function in severely obese type 2 diabetic patients: long-term effects of bariatric surgery. , 2007, Diabetes care.

[49]  Diederick E Grobbee,et al.  Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. , 2007, JAMA.

[50]  G. Guyatt,et al.  Patient-important outcomes in diabetes—time for consensus , 2007, The Lancet.

[51]  Alexander L. Miller,et al.  The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. , 2004, The Journal of clinical psychiatry.

[52]  A. Farmer,et al.  Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. , 2007, The New England journal of medicine.

[53]  David O. Meltzer,et al.  Patient Perceptions of Quality of Life With Diabetes-Related Complications and Treatments , 2007 .

[54]  [Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. (A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes)]. , 2007, Problemy endokrinologii.

[55]  R. Rosenheck.  Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics , 2007, British Journal of Psychiatry.

[56]  Alan C. Evans,et al.  Focal Gray Matter Changes in Schizophrenia across the Course of the Illness: A 5-Year Follow-Up Study , 2007, Neuropsychopharmacology.

[57]  Pharmacotherapy of fi rst-episode schizophrenia , 2008 .

[58]  J. Leahy.  Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes , 2008 .

[59]  D. Owens,et al.  Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial , 2008, The Lancet.